Journal Information
Statistics
Follow this link to access the full text of the article
Special collaboration
Will 68Ga PSMA-radioligands be the only choice for nuclear medicine in prostate cancer in the near future? A clinical update
¿Constituirán en el futuro los radioligandos de 68Ga-PSMA la única elección de la Medicina Nuclear para el cáncer de próstata? Actualización clínica
Vincenzo Cuccurulloa,
, Giuseppe Danilo Di Stasioa, Laura Evangelistab, Andrea Ciarmielloc, Luigi Mansid
Corresponding author
a Nuclear Medicine Unit, Department of Clinical and Experimental Internistic “F. Magrassi – A. Lanzara” – University of Campania Luigi Vanvitelli, Napoli, Italy
b Radiotherapy and Nuclear Medicine Unit, Istituto Oncologico Veneto (IOV–IRCCS), Padova, Italy
c Department of Nuclear Medicine, S. Andrea Hospital, La Spezia, Italy
d Interuniversity Research Centre on Sustainable Development (CIRPS), Roma-Napoli, Italy